

FINAL  
PROGRAMME

Meeting Chair  
Rajesh Taneja

New  
Delhi

17-19  
November  
2016



ESSIC

International Society for the Study of Bladder Pain Syndrome

## ESSIC PRESIDENT MESSAGE



Dear Friends and Colleagues,  
You are warmly invited to attend the important ESSIC meeting in New Delhi this year.

ESSIC “the international society for Bladder Pain Syndrome” has a long tradition of excellent research, education and promotion of the condition. The ESSIC meetings are a must for all those specifically involved in this pathological entity. The wealth of information the participants get, the possibility of networking, the friendly atmosphere and open discussions leave no one untouched. New Delhi is a far trip for participants of parts of the world but you be sure that Dr Taneja and our PCO Defoe will make it worthwhile.

Hope to see you there, nice to have you here!

Jean Jacques Wyndaele

ESSIC President

## MEETING CHAIR MESSAGE



Dear Friends,  
It is my proud privilege to invite you for the annual meeting of ESSIC, to be held in New Delhi, India between 17-19 November 2016. Bladder pain syndrome, erstwhile known as Interstitial Cystitis, has been considered an elusive disease, with varying definitions to diverse clinical presentations.

Delhi is equally diverse in its cultural and historical heritage. The annual meeting would be conducted in comfortable ambience and would include one and a half day of deliberations by experts from all over the world. The following day would be a workshop for the clinicians, who intend to sensitize themselves with the basics of clinical approach to patients of BPS/IC, as presented by the stalwarts from the globe. I am sure this meeting is going to be a scientific bonanza for the experts as well as the beginners alike.

Looking forward to welcoming you all to the pleasant weather of November in New Delhi.

Rajesh Taneja

ESSIC 2016 Meeting Chair

# SCIENTIFIC PROGRAMME

THURSDAY, NOVEMBER 17<sup>th</sup>, 2016

14.30 Registration  
15.00 Welcome and Introduction  
R. Taneja, ESSIC 2016 Meeting Chair  
J.J. Wyndaele, ESSIC President

## Session ONE | Current Understanding of Etiopathogenesis of BPS Moderators: M. Cervigni, P.N. Dogra, D. Shoskes

15.15 Current scenario of multifactorial origin hypothesis  
15.30 Role of the adrenergic system  
15.45 Current epidemiology – are we convinced with our reporting strategies?  
16.00 Impact of etiopathogenesis on planning management of a given case  
16.15 Discussion

16.30 TEA BREAK 

S. Pandey  
R. Taneja  
M. Cervigni  
S. Priyadarshi

## Session TWO | Laboratory markers of the disease: Current and future Moderators: N.P. Gupta, P. Hanno, S. Pandey

17.00 Feasibility of Screening tests for epithelial permeability P. Hanno  
17.15 Correlation of lab markers with symptom complex A. Jain  
17.30 Role of Gut and Urinary Microbiome in Pelvic Pain D. Shoskes  
17.45 Management protocol of BPS as in my centre N. Mishra  
18.00 Discussion

19.00 - 21.30

MEET THE FACULTY   
Welcome Reception & Buffet Dinner  
in the Central Lawn of the Hotel

## FRIDAY, NOVEMBER 18<sup>th</sup>, 2016



### Session THREE | Clinical phenotyping, How feasible is it?

Moderators: A. Goel, J. Nordling, D. Shoskes

- 09.00 Introduction and Classifications based on clinical phenotyping  
09.15 Round Table | Management strategy based on clinical phenotyping and prediction of response to therapy  
P. Hanno, J. Nordling, D. Shoskes, J.J. Wyndaele  
10.00 Proposed Protocol for a future multi centric clinical study  
10.15 Discussion

10.30 TEA BREAK 



### Session FOUR | Pharmacologic aspects of treatment of BPS

Moderators: A. Kriplani, R. Sood, J.J. Wyndaele

- 11.00 Oral PPS: The current understanding  
11.15 NON PPS oral agents  
11.30 Intra vesical agents  
11.45 Future trends in Pharmacological management of BPS and role of Cyclosporine  
12.00 Discussion

P. Hanno

J. Nordling

U. Mete

C. Riedl

J.J. Wyndaele

D. Shoskes

12.15

### SPONSORED SYMPOSIUM | Chairs: P. Hanno, C. Riedl, J. Nordling

Why all Polysaccharoroids are not Pentosan

12.45

LUNCH 



### Session FIVE | Non pharmacological aspects of treatment of BPS

Moderators: U. Mete, N. Mishra, R. Sharma

13.45

Why do treatments fail

R. Taneja

14.00

Role of diet

J.J. Wyndaele

14.15

Current status of neuromodulation

A. Goel

14.30

Role of Physical Rehabilitation in treatment of BPS

N. Purohit

14.45

Discussion

15.00

TEA BREAK 



## Session SIX | Podium presentation

Moderators: S. Priyadarshi, D. Shoskes, J.J. Wyndaele

- 15.30 **1 | Effects of Combination Treatment of Intravesical Resiniferatoxin Instillation and Hydrodistention in Patients with Refractory Painful Bladder Syndrome/Interstitial Cystitis: A Pilot Study**  
Bae Jae Hyun, Choi Hoon
- 15.40 **2 | The factors predicting therapeutic effect of hydrodistension for interstitial cystitis/bladder pain syndrome patients**  
Lee Kyu-Sung, kim Tae Heon, Ko Kwang Jin, Kim Dae Kyung
- 15.50 **3 | The efficacy of endoscopic ablation of the Hunner's lesion in patients with interstitial cystitis**  
Lee Kyu-Sung, Ko Kwang Jin, Kim Dae Kyung
- 16.00 **4 | Phantom pain after Robotic Cysto-Prostatectomy for Bladder Pain Syndrome**  
Kumar Venkatesh, Abdul Rouf Malik, Paul Sagorika, Taneja Rajesh
- 16.10 **5 | Therapeutic trial of Oral Pentosan Polysulfate in post TURP Non Obstructive LUTS**  
Kumar Venkatesh, Abdul Rouf Malik, Paul Sagorika, Taneja Rajesh
- 16.20 **6 | A prospective randomized study of Intra-Vesical sodium Chondroitin Sulfate soln. 2.0% (Uracyst ) and a mixture of Heparin + Xylocaine for the treatment of Painful Bladder Syndrome/IC**  
Shimpi Rajendra, Shimpi Manasi

- 16.30 **7 | Clinical experience with intravesical heparin cocktail therapy in Bladder Pain Syndrome/ Interstitial Cystitis**  
Jain Amita, Ahlawat Rajesh
- 16.40 **8 | Tips and Tricks for Intravesical Injection of Botulinum Toxin in Bladder Pain. Syndrome/Interstitial Cystitis**  
Jain Amita, Suryavanshi Manav, Ahlawat Rajesh
- 16.50 **9 | Effect of the SHIP1 Activator, AQX-1125, on Pain in Rat Models of Cystitis and Prostatitis**  
Cross Jennifer, Stenton Grant, Harwig Curtis, Tam Pat, Toews Judy, Mackenzie Lloyd
- 17.00 **10 | A randomised placebo controlled study of Intravesical instillations of heparin and alkalized lidocaine in refractory interstitial cystitis/Bladder pain syndrome (IC/BPS) –a tertiary centre experience**  
Priyadarshi Shivam, Pathak Ujwal

19.00 - 22.00 **FACULTY DINNER**



## SATURDAY, NOVEMBER 19<sup>th</sup>, 2016

09.00 Registration for Workshops  
09.15 Welcome address  
J.J. Wyndaele, ESSIC President

09.30 - 11.00 | Workshops Session ONE  
HALL A | Etiopathogenesis of the subject - Moderators: P. Hanno, U. Mete  
HALL B | For patients - Moderators: A. Jain, N. Mishra, J. J. Wyndaele

11.00 TEA BREAK 

11.30 - 13.00 | Workshops Session TWO  
HALL A | Investigations in a case of suspected BPS - Moderators: R. Taneja, R. Tanwar  
HALL B | Physiotherapy and rehabilitation - Moderators: N. Purohit, R. Sharma

13.00 LUNCH 

14.00 - 15.30 | Workshops Session THREE  
HALL A | Diagnosis of BPS - Moderators: A. Goel, J. Nordling

15.30 TEA BREAK 

16.00 - 17.30 | Workshops Session FOUR  
HALL A | Clinical approach to a suspected case of BPS - Moderators: S. Pandey, J.J. Wyndaele

## NON DISCUSSED POSTERS

**11 | Increased Fibrosis and mast cells in non-Hunner type /Severe Inflammation and urothelial denudation in Hunner type : Immunohistochemical analysis and Clinical implication in Interstitial Cystitis/B**

Choo Myung-Soo, Kim Aram, Cho Yong-mi

**12 | Longitudinal Changes of Distribution of Hunner Lesion in Patient with Interstitial Cystitis/Bladder Pain Syndrome**

Choo Myung-Soo, Shin Jung-Hyun, Kim Aram

**13 | Mesenchymal stem cells improved bladder function and histopathological features in protamine sulfate-lipopolysaccharide induced interstitial cystitis in rat bladder**

Choo Myung-Soo, Kim Aram, Ryu Chae-Min, Yu Hwan Yeul, Han Ju Young, Shin Dong-Myung

**14 | Quetiapine fumarate extended release in the treatment of Bladder Painful Syndrome with nonurological associated conditions: an exploratory study**

Giannantoni Antonella, Gubbiotti Marilena, Rossi de Vermandois Jacopo Adolfo, Quadrini Francesca, Salvini Eleonora

**15 | Treatment of bladder pain syndrome / interstitial cystitis using combined therapy of hyaluronic acid and alphablockers**

Zabkowski Tomasz, Saracyn Marek

**16 | Intratriganal Botulinum Toxin-A in refractory patients of Painful Bladder Syndrome/IC**

Shimpi Rajendra, Shimpi Manasi

17 | Laparoscopic cystectomy in a patient with Interstitial Cystitis / Bladder Pain. Syndrome (IC/BPS) : Taking the advantage of minimally invasive approach.

Mete Uttam, Mukhopadhyay Abhinandan, Bishnoi Ksitij

18 | Botulinum A Toxin reduces the expression of Vanilloid and Cannabinoid receptors in “in vitro” primary human smooth muscles cell cultures: preliminary results.

Maulà Vincenza, Bistoni Onelia, Nardicchi Vincenza, Salvini Eleonora, Gubbiotti Marilena, Rossi de Vermandois Jacopo A, Giannantoni Antonella

19 | The molecular biologic study about the circadian rhythmic control of micturition function

Kim Khae Hawn, Kim Su Jin, Chung Kyung Jin

20 | Retrospective study of BPS patients

Mehta Chaitasy

21 | The Leadership 301 Trial: Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome

Biagi Heidi, Scholl Dorothea, Butterfield Noam, Green David, Mackenzie Lloyd, Main David

22 | Interstitial Cystitis : A Gynaecological Perspective

Singh Tanvir

23 | Effects on sexual function of women with refractory interstitial cystitis/bladder pain syndrome after instillations of heparin and alkalized lidocaine – a randomised placebo controlled study

Priyadarshi Shivam, Dhakad Devender



## FACULTY

Mauro Cervigni, Urologist and Gynaecologist, Rome  
Prem Nath Dogra, Urologist, New Delhi  
Apul Goel, Urologist, Uttar Pradesh  
Narmada P. Gupta, Urologist, New Delhi  
Philip Hanno, Urologist, Philadelphia  
Amita Jain, Gynaecologist, New Delhi  
Alka Kriplani, Gynaecologist, New Delhi  
Uttam Mete, Urologist, New Delhi  
Nagendra Mishra, Urologist, New Delhi  
Jørgen Nordling, Urologist, Copenhagen  
Sanjay Pandey, Urologist, New Delhi

Shivam Priyadarsh, Urologist, Rajasthan  
Navita Purohit, Physiatrist, Mumbai  
Claus Riedl, Urologist, Austria  
Ranjana Sharma, Gynaecologist, New Delhi  
Daniel Shoskes, Urologist, Cleveland  
Rajeev Sood, Urologist, New Delhi  
Rajesh Taneja, Urologist, New Delhi  
Raman Tanwar, Urologist, Gurgaon  
Jean Jacques Wyndaele, Urologist, Antwerp

## ESSIC EXECUTIVE COMMITTEE

Jean-Jacques Wyndaele, President (Antwerp, Belgium)  
Mauro Cervigni, Vice President (Rome, Italy)  
Joop P van de Merwe, Secretary/Treasurer (Rotterdam, The Netherlands)  
Jørgen Nordling, Member, (Copenhagen, Denmark)  
Phil Hanno, Member (Philadelphia, USA)  
Magnus Fall, Member (Göteborg, Sweden)

PLATINUM, GOLD, SILVER SPONSOR



Sponsored symposium

Friday 18 November | 12.15 - 12.45

Why all Polysaccharides are not Pentosan

Pentosan Polysulfate Sodium is a complex polysaccharide, derived from Xylan of German Beechwood Origin. Xylan is present in abundance in nature & can be extracted from variety of sources, including corn, oats, barley, to hardwood sources like beech and eucalyptus. They are diverse in structure, the chemical modification defines the biological effect of the mother structure.

The key factors in processing polysaccharides from nature for human use are identification of the right source, proper extraction, followed by appropriate modification as necessary. Natural sources determine the backbone of the structure of the molecule. Substances like xylan, although present in all plant sources, have different side units and modifications depending on the plant. Any alteration / replacement or compromise in the plant source will cause a difference in the structure of the final active material, thus impacting the efficacy of the molecule.

An inferior product, which is not extracted from the right source by the right method, will adversely effect the interests and confidence of the patients. A product like pentosan takes nearly 6 months to show efficacy, the current patients suffering with this debilitating disease do not have any other drug alternate in the market, nor do they have any reliable safe drugs in the pipeline from pharmaceutical companies. Besides, the drug cannot be traced in the blood, further complicating regulatory controls to establish reliable efficacy of the molecule.

In such a scenario, it is our obligation and responsibility to protect the sanctity of the only medicine available for the suffering patients, and not only that, but also take forward the progress of this science from understanding, to enhancing the efficacy parameters, such that the stake holders can progress the disease solutions to improve the quality of life of such patients. With such challenges, we have successfully brought to market a very reliable, efficacious and credibility established generic, equivalent to the originator via rigorous scientific validation over a decade of work done at prestigious Mt Sinai School of Medicine, USA.

OTHER EXHIBITORS AND SPONSORS



## GENERAL INFORMATION

Doctors interested in registering and companies interested in sponsoring or exhibiting at the event are invited to contact the organizing secretariat at [essic@defoe.it](mailto:essic@defoe.it)

## REGISTRATION COSTS

Send registration form to the organizing secretariat together with the receipt of payment, made before 15 October 2016. After this date, registration will still be possible during the event, until reaching the maximum number of participants.

	Until 15 October	After 15 October
MD, MhD	€ 200,00*	€ 300,00*
MD, MhD (ESSIC Members)	€ 150,00*	€ 250,00*
Nurse & Care Workers	€ 100,00*	€ 200,00*
Students & Residents	€ 50,00*	€ 50,00*
Patients	€ 50,00*	€ 50,00*

\* Fee is meant for each person, in Euros, VAT free.

The registration fee includes: certificate of attendance, CME related forms, coffee breaks and lunch, Meet the Faculty, free entrance to the exhibition area.

## Registration: on site

The registration and help desk times are as follows

THURSDAY 17 November: 14.00-17.45

FRIDAY 18 November: 09.00-18.00

SATURDAY 19 November: 09.00-17.30

## UEMS Accreditation requested

UEMS application has been filed and is currently under evaluation for Physicians, Gynecologists, Urologists, Surgeons, Neurologists, Gastroenterologists, Anesthetists.

## MEETING VENUE

Four Points by Sheraton New Delhi, Airport Highway

Address: Plot No 9, National Highway 8, Delhi - Gurgaon Road, Samalka, New Delhi, Delhi 110037, India

defoe®

Organizing Secretariat

T. +39.0523.338391 | [essic@defoe.it](mailto:essic@defoe.it) | [www.defoe.it](http://www.defoe.it)

Platinum, Gold, Silver Sponsor



**COMFORA**

Pentosan Polysulfate Sodium

The Congress App "ESSIC 2016"  
is now available for download!

